Sexually Dimorphic Changes of Hypocretin (Orexin) in Depression by Lu, J. et al.
EBioMedicine 18 (2017) 311–319
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comResearch PaperSexually Dimorphic Changes of Hypocretin (Orexin) in DepressionJing Lu a,b, Juan Zhao c, Rawien Balesar c, Rolf Fronczek d, Qiong-Bin Zhu a, Xue-Yan Wu a, Shao-Hua Hu a,b,
Ai-Min Bao a,⁎, Dick F. Swaab a,c
a Department of Neurobiology, Key Laboratory ofMedical Neurobiology ofMinistry of Health of China, Zhejiang Province Key Laboratory ofMental Disorder's Management, Zhejiang Province Key
Laboratory of Neurobiology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, PR China
b Zhejiang Province Key Laboratory of Mental Disorder's Management, Department of Psychiatry, First Affiliated Hospital, Zhejiang University School of Medicine
c Netherlands Institute for Neuroscience, an Institute of the Royal Netherlands Academy of Arts and Sciences, Meibergdreef 47, 1105 BA Amsterdam, The Netherlands
d Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands⁎ Corresponding author.
E-mail address: baoaimin@zju.edu.cn (A.-M. Bao).
http://dx.doi.org/10.1016/j.ebiom.2017.03.043
2352-3964/© 2017 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 14 November 2016
Received in revised form 27 March 2017
Accepted 27 March 2017
Available online 31 March 2017Background:Neurophysiological and behavioral processes regulated by hypocretin (orexin) are severely affected
in depression. However, alterations in hypocretin have so far not been studied in the human brain. We explored
the hypocretin system changes in the hypothalamus and cortex in depression from male and female subjects.
Methods:We quantified the differences between depression patients and well-matched controls, in terms of hy-
pothalamic hypocretin-1 immunoreactivity (ir) and hypocretin receptors (Hcrtr-receptors)-mRNA in the anteri-
or cingulate cortex (ACC) and dorsolateral prefrontal cortex. In addition, we determined the alterations in the
hypocretin system in a frequently used model for depression, the chronic unpredictable mild stress (CUMS) rat.
Results: i) Compared to control subjects, the amount of hypocretin-immunoreactivity (ir) was significantly in-
creased in female but not inmale depression patients; ii) hypothalamic hypocretin-ir showed a clear diurnal fluc-
tuation, which was absent in depression; iii) male depressive patients who had committed suicide showed
significantly increased ACC Hcrt-receptor-2-mRNA expression compared to male controls; and iv) female but
not male CUMS rats showed a highly significant positive correlation between the mRNA levels of corticotro-
pin-releasing hormone and prepro-hypocretin in the hypothalamus, and a significantly increased Hcrt-recep-
tor-1-mRNA expression in the frontal cortex compared to female control rats.
Conclusions: The clear sex-related change found in the hypothalamic hypocretin-1-ir in depression should be







In individuals vulnerable to depression and suicide an exaggerated
reaction to environmental stressors, such as life events, is found in the
stress-regulating systems of the brain (Turecki et al., 2012). This
hyper-reactivity stems from the interaction of genetic, early develop-
mental and environmental factors (Sun et al., 2013). The
hypothalamo-pituitary-adrenal (HPA) axis holds a prominent position
in the network mediated by stress- and reward-related neurotransmit-
ters and neuromodulators, and is significantly affected in depression
(Bao et al., 2012) and suicide (Turecki et al., 2012).In depression, the hy-
pothalamic paraventricular nucleus (PVN), which is the regulating cen-
ter of the HPA-axis, shows not only an increased production of
corticotropin-releasing hormone (CRH) (Raadsheer et al., 1995; Bao et
al., 2005), but also changes in the expression of certain CRH-activity-re-
lated receptors that render the PVN more sensitive to stress (Wang etan open access article underal., 2008). Both increased CRH and increased corticosteroid levels may
induce depressive-like behavioral changes (Holsboer, 2001).
Hypocretin-producing neurons are localized in the hypothalamus
(Hunt et al., 2015) and act via their two G-protein-coupled receptors,
hypocretin receptor-1 and -2 (Hcrt-receptor-1 and Hcrt-receptor-2)
(Sakurai et al., 1998). Hypocretin projections and Hcrt-receptors are
found in many brain areas, including the prefrontal cortex (PFC)
(Peyron et al., 1998). It is of interest to note that the neurophysiological
and behavioral processes regulated by hypocretin, such as the sleep-
wake cycle, food intake, sexual behavior, and stress response, are se-
verely affected in depression (Nollet and Leman, 2013). Several studies
have indicated the possible involvement of the hypocretin system in de-
pression with suicide. For example, reduced CSF hypocretin levels were
observed in suicidal patients with major depressive disorder (MDD)
compared with patients suffering from adjustment disorder or dysthy-
mia with suicide attempts (Brundin et al., 2007a). In addition, signifi-
cant negative correlations were found between CSF-hypocretin levels
and the symptoms of lassitude (difficulty to initiate activities) and slow-
ness of movement, as well as the ratings of global illness (Brundin et al.,
2007b). Hypocretin has close functional interactions with the HPA-axis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stress (Winsky-Sommerer et al., 2004). Hcrt-receptor antagonists
were found to attenuate anxiety and panic-like behaviors associated
with stress or hyperarousal states in rat (Johnson et al., 2015;
Bonaventure et al., 2015). Moreover, the changes in the transcripts for
the Hcrt-receptor-1 and Hcrt-receptor-2 were found to be divergent,
i.e. Hcrt-receptor-1 increased, while Hcrt-receptor-2 decreased in the
basolateral amygdala in chronically stressed c57bl/6 mice (Arendt et
al., 2014). A clinical study of single-nucleotide polymorphisms sug-
gested that the hcrt-receptor-1 gene, or a linked locus, may modulate
the risk for mood disorders (Rainero et al., 2011). This possibility was
confirmed in hcrt-receptor-1 knockout mice, which showed increased
anxiety-like behavior and altered depression-like behaviors (Abbas et
al., 2015). These data indicate that the hypocretin systemmay have a bi-
directional regulatory capacity in terms of the stress response.
In light of the data mentioned above, we hypothesized that the
hypocretin/orexin systemmayplay a role in the pathogenesis of depres-
sion and suicide, possibly by interaction with the HPA-axis. To test this
possibility, we measured hypocretin-1 expression in its production
area, the postmortem hypothalamus. Second, Hcrt-receptors-mRNA
content was determined in the PFC of depressive patients, some of
whom had committed suicide. Finally, we determined prepro-
hypocretin-mRNA and CRH-mRNA in the hypothalamus and Hcrt-re-
ceptors-mRNA levels in the frontal cortex in a frequently used animal
model for depression, i.e. chronic unpredictable mild stress (CUMS)
rats. Because of the clear sex differences in depression and suicide, spe-
cial attention was given to the possible sex differences, both in the
human and in the animal studies (Bao and Swaab, 2011).
2. Materials and Methods
2.1. Part I: Post-mortem Brain Material Study
In total, 120 human post-mortem samples were studied: 32
hypothalami and 52 cortex samples from the Netherlands Brain Bank
(NBB), and 36 cortex samples from the Stanley Medical Research Insti-
tute (SMRI). Informed consent for a brain autopsy and for the use of the
brain material and medical records for research purposes was given by
the donor or their next of kin.
The chronic mood disorder patients and their controls were well-
matched for confounding factors, including age, sex, postmortem
delay, fixation time, clock time of death, month of death, CSF-pH (a
measure of agonal state), brain weight and Braak stages of Alzheimer's
pathology (Braak and Braak, 1991). Clinico-pathological details and p-
values of matching are given in Table 1 and Supplementary Tables 1–
2. The diagnosis ofMDDor bipolar disorder (BD)was confirmed accord-
ing to the Diagnostic and Statistical Manual of Mental Disorders IV by
qualified psychiatrists using the extensive medical records of the NBB,
which also contained well-documented diagnoses and onset of depres-
sion from psychiatric clinics. Exclusion criteria for control subjects were
in the first place the use of corticosteroids, as they inhibit the CRH cells
in the human hypothalamus (Watts, 2005), which may subsequently
influence the hypocretin system (Brunton and Russell, 2003). In addi-
tion, primary neurological or psychiatric diseases were exclusion
criteria, unless stated otherwise. The absence of pathology was verified
in all subjects by a systematic neuropathological analysis (Fronczek et
al., 2007; Gao et al., 2013).
2.1.1. Immunocytochemistry and Quantification
The hypothalami were fixed in 10% PBS (pH 7.4) formalin at room
temperature and were paraffin-embedded and serially-sectioned at 6
μm in rostro-caudal direction. Hypothalami of 16 mood disorder pa-
tients, i.e. 9 MDD and 7 BD patients, and 16 control subjects were
used. Every 100th section of 6 μm thickness in the expected hypocretin
cell area was stained using a hypocretin-1 antibody (catalog no. H-003-
30, Phoenix Pharmaceuticals, Inc., Belmont, CA, USA) at 1:20,000dilution. The specificity of the antibody had been confirmed in our pre-
vious study (Fronczek et al., 2007). In addition,we stained the hypothal-
amus of a narcoleptic patient as a negative control whose hypothalamus
was indeed virtually devoid of hypocretin-1-immunoreactive (ir)
neurons.
Hypocretin-1-ir was quantified by the image analysis procedure de-
scribed in our previous studies (Gao et al., 2013). In brief, the set-up
consisted of an image analysis system (Image Proversion 6.3, Media Cy-
bernetics, Rockville, USA) connected to a black andwhite camera (SONY
XC-77E) mounted on a microscope (Zeis Axios-kop with Plan-
NEOFLUAR Zeiss objectives, Carl Zeiss GmbH, Jena, Germany). The hy-
pothalamus area covered by hypocretin-stained neurons was outlined
manually at a 20× objective. The threshold for the positive signal was
set at twice the optical density (OD) of the background. The computer
determined the OD of the pixels and percentage surface area covered
by the signal (area mask). The integrated optical density (IOD) was cal-
culated by multiplying the OD by the masked area corrected for back-
ground. For each subject, the total IOD was calculated as the final
parameter for the total amount of Hypocretin-1-ir, by a conversion pro-
gram based uponmultiplication of the separate IOD by sample frequen-
cy of the sections, as described previously (Goldstone et al., 2002).
Completeness of the hypocretin-1-ir in the hypothalamus was con-
firmed by graphically presenting the IODs measured in every section
from rostral to caudal, with a line drawn by the excel trend-line option
‘Moving Average’. The value under each curve showed the total IOD of
the subject (see Fig. 1A–B). The total IOD of hypothalamic hypocretin-
1-ir as determined by computer-assisted morphometry is not only an
objective method but also less time-consuming than neuron-counting.
In addition, the IOD shows a good positive correlation with neuron-
counting (for 35 sections of 2 patients and 2 controls, rho = 0.781, p b
0.001), performed in the way we described previously (Fronczek et al.,
2007).
2.1.2. Quantitative PCR (qPCR) for mRNA Expression of Hcrt-receptors
In our present study 50 μm cryostat sections of anterior cingulate
cortex (ACC) or dorsal lateral prefrontal cortex (DLPFC) were cut from
the left side of the cortex and the grey matter containing all six layers
was isolated as described before (Gao et al., 2013). Levels of Hcrt-recep-
tor-1- and Hcrt-receptor-2-mRNA were determined by qPCR. Informa-
tion regarding gene selection and primers are shown in
Supplementary Table 3. RNA isolation, cDNA synthesis and qPCR were
performed as described before (Wang et al., 2008).
In addition, a normalization strategy was used to remove sampling-
related differences in RNA quantity (Wang et al., 2008). The expression
of target genes was normalized using the sets of stable reference genes,
including actin-beta (ACTb), glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), hypoxanthine phosphoribosyltransferase 1 (HPRT1),
and ubiquitin-C for the postmortem human brain study, while ACTb,
GAPDH, HPRT1, and elongation factor-1 alpha (EF1α) for the animal
study (see below).
2.2. Part II: Animal Study
Adult Sprague Dawley male (n = 12, 280–300 g, ~8 weeks of age)
and female (n = 24, 230–250 g, ~8 weeks of age) rats were randomly
divided into a control and a CUMS group. CUMS was applied according
to our previous study (Lu et al., 2015). Briefly: this involved a three-
week daily exposure to alternating stressors alongwith occasional over-
night stressors. The following stressors were given in random order:
damp bedding (300 ml of water spilled in the bedding), 40°-cage-tilt
along the vertical axis, paired housing, exposure to an emptywater bot-
tle for 1 h immediately following a period of acute water deprivation
(25 h from 0900 h until 1000 h the next day), stroboscopic illumination
(300 flashes/min), and white noise. Body weight was assessed weekly
during the CUMS procedure, and an open field test for anxiety-behavior
(Chen et al., 2009) and sucrose preference test for depression-like
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the CUMS paradigm. In the open field testwemeasured the distance the
rat travelled in the field, the time spent in the central squares, together
with the number of grid lines crossed. In the 5% sucrose preference test
sucrose preferencewas determined by the ratio of theweight of sucrose
solution versus water consumed during the 24 h.
2.2.1. Tissue Collection
Rats were sacrificed by decapitation between 0900 h and 1000 h
upon conclusion of the behavioral tests. Female rats, both of the control
and CUMS groups, were sacrificed, in equal numbers, in proestrus or di-
estrus. Trunk blood, hypothalamus and frontal cortex were collected.
The hypothalamus and frontal lobe were immediately dissected, frozen
in liquid nitrogen and stored at −80 °C until assayed.
All animal experimental procedures were approved by the local an-
imal care committee of Zhejiang University in accordance with the rel-
evant regulations and laws.
2.2.2. Sample Measurement
Plasma corticosterone (CORT) levels were assayed by ELISA
(RE52211, IBL Corporation, USA). Hypothalamic mRNA levels of
prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 andCRH, and fron-
tal cortexmRNA levels of Hcrt-receptor-1 andHcrt-receptor-2were de-
termined by qPCR. The primers were designed by Primer Premier
(version 5.0) to amplify specific amplicons. Sequences and size of the
primer pairs are shown in Supplementary Table 3. The RNA isolation
and qPCR were performed as described before by our group (Wang et
al., 2008).
2.3. Statistics
As the data were not always normally distributed, non-parametric
tests were applied. Differences between 2 groups were tested using
the Mann-Whitney U test. Differences among the 3 groups were first
tested with Kruskal-Wallis (K-W), and if a significant difference was
identified, the difference between 2 groups was checked with the
Mann-Whitney U test. Generalized linear model (GLM) was applied to
analyze the contribution of certain factors to the changes observed in
Hypocretin-1-ir (see Section 3). Correlations were examined with the
Spearman's test. Differences in clock time andmonth of death were an-
alyzedwith theMardia-Watson-Wheeler test. All tests were 2-tailed, p-
values ≤ 0.05 were considered to be significant, while p-value b 0.1 and
N0.05 was considered to be a trend.
3. Results
3.1. Postmortem Human Brain Material
3.1.1. Hypocretin-1 Immunocytochemistry
Hypocretin-1-ir neurons showed the same distribution pattern as
described before (Fronczek et al., 2007), and hypocretin-1-ir was pres-
ent in the cytoplasm and fibers of hypothalamic neurons, both in con-
trols and depressive patients (Fig. 1C–F). Data are presented as
median (25th–75th percentile). The IOD of hypocretin-1-ir showed a
significantly higher level in the depression group compared with the
control group (depression: 0.23 (0.14–0.26); controls: 0·17 (0.10–
0.22), p = 0.050), which appeared to be due to the female depressive
patients, who showed significantly (40%) higher IOD values (0.27
(0.22–0.37)) than the matched female controls (0.19 (0.09–0.21); p =
0.022), while the IOD of hypocretin-1-ir of male depressive patients
(0.17 (0.13–0.23)) showed no significant differences from the control
male subjects (0.15 (0.11–0.22); p= 0.406) (Fig. 2A). GLMwas applied
with depression and sex as the main factors to investigate the effect of
these two factors on hypocretin-1-ir and the interaction between
them. GLM revealed that the interaction between depression and sex
was significant (p = 0.041). The main effect of depression onhypocretin-1-ir remained significant (p = 0.003), as well as the effect
of sex (p = 0.004).
There was no difference in hypocretin-1-ir IOD between the MDD
and BD subgroups (p = 0.874), either between female and male sub-
jects within the control group (p = 0.652) or between female and
male subjects within the control group (p = 0.875). Furthermore,
there were no significant correlations between the IOD of hypocretin-
1-ir with age or with the duration of depression (p ≥ 0.15).
3.1.2. Hypocretin-1-ir Day-Night Fluctuation
In the control group, the IOD of hypocretin-1-ir was significantly
(40%) higher for those with a clock time of death at night (0.20 (0.15–
0.22), 1900 h–0700 h) than for those with a clock time of death during
the daytime (0.09 (0.07–0.17); p = 0.031), whereas such a difference
was not present in the depression subjects (nighttime: median =
0.23; daytime: median= 0.18; p= 0.382, Fig. 2B). The time segmenta-
tion was based upon a previous study on the diurnal rhythm of CSF
hypocretin-1 levels (Salomon et al., 2003). The daytime and nighttime
control subgroups did not differ significantly in terms of possible con-
founders, i.e. age, sex, PMD, FT, or CSF-pH (p ≥ 0.137).
3.1.3. The mRNA Expression of Hcrt Receptors in the ACC and DL PFC
In the cortex samples of the relatively younger patients of the SMRI
series (depression: 42 years (24–63 years); controls 46 years (24–
63 years), Supplementary Table 2), both Hcrt-receptor-1- and Hcrt-re-
ceptor-2-mRNA expression were detectable in the ACC and the DLPFC.
No significant differences in ACC Hcrt-receptor-1-mRNA expression
were seen among the 3 groups, i.e. depressive patients who had com-
mitted suicide, depressive patients who had died of causes other than
suicide, and control subjects (K-W: Hcrt-receptor-1, p = 0.102), but
there was a trend for changes in Hcrt-receptor-2-mRNA in these 3
groups (K-W: p = 0.085). We observed a significant difference in
Hcrt-receptor-2-mRNA expression among these 3 groups in male sub-
jects (K-W: p = 0.035), which was subsequently found to be due to
the significantly (38%) higher Hcrt-receptor-2-mRNA levels inmale sui-
cide MDD patients (n = 10) compared with male controls (n = 8, p =
0.015, Fig. 2C). Please note that althoughwe did not observe similar sig-
nificant changes in female subjects or in male subjects who died of
causes other than suicide (K-W: Hcrt-receptors, p ≥ 0.222), the number
of these subgroupswas too small to drawafirm conclusion in relation to
sex difference and/or suicide. In the DLPFC, Hcrt-receptor-1-mRNA ex-
pression showed a significant negative correlation with age in the con-
trol group (rho = −0.887, p = 0.001). No significant changes in Hcrt-
receptors-mRNA expression in the DLPFC were observed, either
among the 3 entire (female + male) groups, i.e. depressive patients
whohad committed suicide, depressive patientswhohad died of causes
other than suicide, and control subjects, or among 3 different female or
male subgroups (K-W: Hcrt-receptors, p ≥ 0.345).
In cortex samples of the relatively older patients (depression:
78 years (45–96 years); controls 73 years (45–90 years), Supplementa-
ry Table 1), which contained only non-suicide depressive patients, Hcrt-
receptor-1-mRNA expression was only detectable in the ACC, while
Hcrt-receptor-2-mRNA expression was only detectable in the DLPFC,
both in the control and in the depression group. In the ACC of these
non-suicide depressive patients there was a trend (p = 0.068, Fig. 2D)
towards lower Hcrt-receptor-1-mRNA expression compared with the
controls. In the DLPFC, no significant differences in Hcrt-receptor-2-
mRNA expression were found between the non-suicide depressive pa-
tients and the control group (p= 0.894). There were no sex differences
in HCRTs either in the ACC or in theDLPFC (p ≥ 0.209). Therewas no sig-
nificant correlation between the duration of depression and theHcrt-re-
ceptors-mRNA levels in the ACC or DLPFC (p ≥ 0.401).
3.1.4. The CUMS Animals
Although the body weight of both female and male rats showed, as
expected, a diminished increase during and after the CUMS procedure
Table 1
Clinico-pathological information of subjects for hypothalamus study.























92-003 MDD F 55/2 4:54 52 07:45 11 6.40 1320 ND BZD, SSRI, TeCA SSRI, BZD,
bromocriptine
Yes Yes Suspected urosepsis,
heart failure
94-032 MDD M 71/2 16:15 38 16:15 2 ND 975 ND ZUC, BZD, MAOI,
digoxine




94-017 MDD F 72/20 22:00 39 19:00 1 ND 1287 ND TeCA, BZD,
prednison
None NO No Bronchopneumonia,
mesothelioma
12-097 MDD F 73/9 5:45 61 15:30 9 6.70 1205 ND TeCA TCA, TeCA, BZD,
pancuronium, Ba
No No Heart failure, legal
euthanasia




Yes Yes Suicide by hanging
02-051 MDD M 81/34 15:30 34 15:30 6 6.50 1345 3 None Hal No No Renal insufficiency





No No PTSS with depression,
acute heart failure








08-031 MDD F 93/63 4:20 51 04:55 3 6.80 1023 2 SSRI, BZD Mo, BZD, SSRI Yes Yes Pneumonia
02-014 BD M 68/26 12:00 30 00:00 2 6.64 1424 1 Li, Hal, ZUC,
MAOI
MAOI No No Subdural hematoma
99–118 BD M 68/30 5:55 33 23:15 10 6.82 1204 1 Li, SSRI Li Yes No Cardiac ischemia
00–111 BD M 70/35 4:50 43 02:45 10 6.26 1490 1 Li, ZUC,
valproate, BZD
Li, ECT No No Cardiac arrest, ileus
due to intestinal
haemorrhage





Yes No Cachexia, dehydration
98-010 BD F 75/20 4:00 38 20:45 1 ND 1123 1 TeCA, TCA BZD, TeCA, SSRI,
Hal, Mo





12-048 BD M 81/15 6:40 60 20:00 5 6.70 1283 1 Li, prednisolon Li, BZD,
amitriptyline,
valproate
No No Legal euthanasia
12-110 BD M 87/10 3:15 53 23:00 10 6.39 1285 3 BZD, valproate BZD, Mo,
valproate
No No CVA, pneumonia
Median – – 76/20 5:50 44 15:30 6 6.51 1271 – – – – – –
99-033 CTR F 61 17:45 119 23:15 12 ND 1296 0 None None – – Acute heart failure,
gastric blood loss
97-042 CTR F 65 12:50 28 02:00 4 6.94 910 1 None Adrenalin – – Cardiac arrest,
pneumonia,
pulmonary oedema
99-101 CTR M 69 19:15 41 03:30 8 6.40 1352 1 None βB, Hal, BZD – – Pneumonia
92-049 CTR M 71 5:40 32 12:00 4 7.40 1250 ND None None – – Found death
08-032 CTR M 71 8:55 70 03:15 3 6.64 1520 2 Mo Mo – – Pancreas carcinoma,
rectum carcinoma with
hepatic metastases
98-104 CTR F 74 7:25 31 09:50 7 6.95 1167 2 BZD BZD, βB – – Necrosis of the
intestines secondary to
thrombosis
95-106 CTR M 74 8:00 60 13:00 11 6.75 1317 0 None Dopamine – – Myocardial infarction
06-028 CTR M 76 19:35 27 20:00 4 6.50 1514 3 None None – – Prostate carcinoma,
cardiac arrest
94-039 CTR M 78 53 88 12:00 1 ND 1354 ND None Nitroglycerine – – Myocardial infarction
99-116 CTR M 78 4:20 43 16:15 9 ND 1310 0 None Mo, BZD – – Pancreatic cancer
95-006 CTR M 81 8:25 28 04:45 1 6.70 1274 1 None ND – – Cardiogenic shock




– – Acute myocardial
infarction








09-001 CTR M 88 4:43 51 19:47 1 6.17 1418 2 None None – – Gastro-intestinal
bleeding
08-105 CTR F 89 3:52 58 12:10 12 7.30 1258 3 prednisolone Hal, digoxine,
Mo
– – Pneumonia
08-054 CTR F 92 7:00 67 09:45 6 6.55 1230 1 Digoxine,
prednison
prednison – – Acute death, probably
pulmonary embolism
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Table 1 (continued)























Median – – 77 7:52 43 12:00 5 6.7 1285 – – – – – –
p-Value – – 0.616 0.361 0.780 0.711 0.93 0.137 0.515 – – – – – –
Note: βB, beta-blocker; Ba, barbiturate; BD, bipolar disorder; Braak stage, progression of pathological changes for Alzheimer's disease according to Braak and Braak, 1991; BW, brain
weight; BZD, benzodiazepine; CSF, cerebrospinal fluid; CTD, clock time at death; CTR, control; CVA, cerebrovascular accident; ECT, electroshock treatment; F, female; FT(d), fixation
time in days; F, female; Hal, haloperidol; Li, lithium; M, male; MAOI, monoamine oxidase inhibitor; MDD, major depressive disorder; Mo, morphine; MOD, month of death; NBB, Nether-
lands Brain Bank; ND, no data; None, nomedication; NSAIDs, nonsteroidal anti-inflammatory drugs; PMD, postmortem delay; PTSS, posttraumatische stressstoornis; SSRI, selective sero-
tonin reuptake inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressants; ZUC, zuclopenthixol. a: Patient also be diagnosis with post traumatic stress syndrome. b: Patient
also be diagnosis with old cerebrovascular accident mildly demanded.
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depression-like (sucrose preference tests, Supplementary Fig. 1B) and
anxiety-like (open field test) behaviors (Supplementary Fig. 1C–E).
Plasma CORT levels were significantly increased both in female and
male (p ≤ 0.008) CUMS rats (Fig. 3A). It should be noted that we pooled
these female rats for the correlation analysis, since we did not observe a
significant difference in the plasma CORT levels, hypothalamic mRNA
levels of prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 and CRH,
and frontal cortex mRNA levels of Hcrt-receptor-1 and Hcrt-receptor-
2 between female rats sacrificed in proestrus and in diestrus, we pooled
these female rats for the correlation analysis. The Hcrt-receptor-1-
mRNA expression was significantly higher in the frontal cortex of fe-
male CUMS rats (0.012 (0.009–0.017)), compared with the female con-
trol rats (0.008 (0.007–0.010); p = 0.019, Fig. 3B), while male rats did
not show significant alterations in these molecules after CUMS (p ≥Fig. 1. Immunocytochemistry of hypocretin-1. A–B: representative distribution patterns of the
along the hypothalamus. (A) A female depression patient, (B) a male depression patient. C–F:
A female control subject. (D) A female depression patient. (E) A male control subject and (F) a0.328). There were no significant differences in the mRNA expression
of prepro-hypocretin, Hcrt-receptor-1, Hcrt-receptor-2 or CRH in the
hypothalamus between the CUMS and the control rats in either sex (p
≥ 0.234). However, female CUMS rats showed a significant positive cor-
relation between the mRNA levels of CRH and prepro-hypocretin (p =
0.007, rho = 0.775, Fig. 3C), which was absent in male CUMS rats (p
= 0.517, rho = −0.238, Fig. 3D).
4. Discussion
Our study shows, for the first time in postmortem human brain, that
hypothalamic hypocretin/orexin is increased in female - but not inmale
- depressive patients. In addition, there was a diurnal fluctuation in hy-
pothalamic hypocretin-1-ir in the control subjects, whichwas absent in
depression. Moreover, we observed that Hcrt-receptor-mRNAintegrated optical density (IOD) of hypocretin-1 immunoreactivity from rostral to caudal
representative hypocretin-1 staining in the hypothalamus of a female control subject. (C)
male depression patient. Bar = 0·025 mm.
Fig. 2. Changes of hypocretin-1 system in depression. A: Comparison of the amount of hypocretin-1-immunoreactivity (ir) between the entire control (CTR, n = 16) and the entire
depression group (DEP, n = 16), the female CTR (n = 6) and female DEP group (n = 6), and the male CTR (n = 9) and male DEP group (n = 9). B: The amount of hypocretin-1-ir is
on the left side for the CTR group (between nighttime (1900 h–0700 h, n = 9) and daytime (0700 h–1900 h, n = 7), and on the right side (n = 8 vs. n = 8) for the DEP group. The
time segmentation was based upon a study on the diurnal rhythm of cerebrospinal fluid hypocretin-1 levels (Chen et al., 2009). Note the absence of a day-night fluctuation in DEP
patients. C: The hypocretin (Hcrt) receptor-2-mRNA levels in the anterior cingulated cortex (ACC) of the entire group comparison, i.e. CTR (n = 12), major depressive disorder
patients who committed suicide (MDD + suicide, n = 17) and MDD patients who died of causes other than suicide (MDD+ non-suicide, n = 7) on the left side, and for male groups
comparison on the right side. Note that male MDD + suicide patients (n = 10) had significantly higher Hcrt receptor-2-mRNA levels compared with male controls (n = 8). D: The
Hcrt-receptor-1-mRNA levels in the ACC of these non-suicide depressive patients (n = 12) showed a trend for decrease compared with the controls (n = 12).
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Male depressive patients who had committed suicide had significantly
increased ACC Hcrt-receptor-2-mRNA expression. Our data thus indi-
cate sex-, brain area-, age-, and potentially suicide-related changes in
the hypocretin/orexin system in depression. Finally, a significant posi-
tive correlation between hypothalamic CRH-mRNA and prepro-
hypocretin-mRNA and a significant increase in Hcrt-receptor-1-mRNA
expression in the frontal cortex in female - but not male - CUMS rats
strengthen the presence of sexually dimorphic hypocretin/orexin sys-
tem changes in mood disorder.
4.1. Hypocretin-ir in the Hypothalamus in Depression
It should be noted that the increased IOD of hypocretin-ir may indi-
cate an increase in either hypocretin-expressing neuron number (relat-
ed to the area stained) and/or staining intensity (measured as OD). An
increase of either of these parameters indicates an increased expression
of hypocretin protein levels. The significantly increased hypocretin-ir in
female depressive patients indicates that hypocretinmay play a key role
in the etiology of depression,which ismore prevalent in females than in
males (Piccinelli and Wilkinson, 2000). As we have indicated in the In-
troduction section, studies have found that Hcrt-receptor-1 gene, or a
linked locus, may modulate the risk for mood disorders (Rainero et al.,
2011) and Hcrt-receptor-1 gene knockout mice showed increased anx-
iety-like behavior and altered depression-like behaviors (Abbas et al.,
2015). One may thus speculate that the higher levels of hypocretin-1-
ir in female patients may enhance depressive symptoms. It should be
noted that since all the female subjects studied in our study were in
their postmenopausal stage, one would not expect to see the hot
flash-related hypocretin changes reported earlier (Federici et al., 2016).
The sex difference in the alterations of hypocretin, which happens in
the framework of the stress-hypothesis, was further supported by our
animal study, showing a significant positive correlation betweenhypothalamic prepro-hypocretin-mRNA and CRH-mRNA only in female
CUMS rats. In view of this, it is of interest to note that the dual Hcrt-re-
ceptor antagonist almorexantwas found to prevent HPA axis dysregula-
tion caused by CUMS and offers evidence for the possibility that
pharmacological blockade of the hypocretin system induces a robust
antidepressant-like effect as well as the restoration of the stress-related
HPA axis defect (Nollet et al., 2012). It should be noted, however, that
other animal models of depression showed different results in terms
of changes in the hypocretin system, such as the genetically depressed
Wistar-Kyoto male rats, which showed a lower number and size of
hypocretin-1 neurons than its control Wistar male rats (Allard et al.,
2004). In another genetically depressed rat model, i.e. the Flinders Sen-
sitive Line (FSL), the number of hypothalamic hypocretin-positive neu-
rons was higher in female FSL rats than in the female control rats, i.e.
Flinders Resistant Line (FRL) although this publication by Mikrouli et
al. offers no data onmale rats (Mikrouli et al., 2011). It is a frequent phe-
nomenon that animalmodels tend tomimic “just a few symptoms rath-
er than a complete psychiatric disorder”. This is a reason to validate the
data obtained in animal models on human postmortem material.
We found a clear day-night fluctuation in hypothalamic hypocretin-
1-ir in the control subjects, with higher levels at night, which is similar
to the pattern reported for lumbar puncture CSF hypocretin-1 levels ob-
tained by continuous in vivo sampling (Salomon et al., 2003). These
findings are in agreement with the concept that hypocretin neurons
may play a key role in sleep-wake regulation (Saper, 2013), and the ab-
sence of the day-night hypocretin-1-ir fluctuation in depression may
thus relate to the frequently occurring symptoms of sleep disorders in
this condition. It should be noted that in our earlier researchwe demon-
strated a clear diurnal rhythm in the biological clock, the suprachias-
matic nucleus (SCN), for its main neuropeptide, vasopressin, both on
the protein level (Hofman et al., 1993) and on the mRNA level (Zhou
et al., 2001) in postmortem material, when the patients were grouped
according to time of death. Interestingly, a direct projection from the
Fig. 3.A: Plasma corticosterone levels of control (male CTR, n= 6; female CTR, n=12) rats and chronic unpredictablemild stress (CUMS) rats (male CUMS, n=6; female CUMS, n=12).
B: Hypocretin (Hcrt) receptor-1-mRNA expression in frontal cortex of CTR and CUMS rats. Please note that female CUMS rats (n = 12) had significantly higher Hcrt receptor-1-mRNA
levels compared with female controls (n = 12). C: There was a significant positive correlation between prepro-hypocretin-mRNA and corticotropin-releasing hormone (CRH)-mRNA
in the hypothalamus of female CUMS rats (rho = 0·775, p = 0·007, n = 12). D: There was no significant correlation between prepro-hypocretin-mRNA and CRH-mRNA in the
hypothalamus of male CUMS rats (rho = −0·238, p = 0·517, n = 6).
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human (Abrahamson et al., 2001), which indicates that the SCNmay di-
rectly regulate the function of hypocretin-immunoreactive neurons.
Our finding of the absence of a diurnal hypocretin rhythm in depression
agrees with our earlier observation of a diminished SCN function in de-
pression (Zhou et al., 2001). Our data (Zhou et al., 2001) and those of
others (Li et al., 2013) thus also show that postmortem studies can in-
deed reflect the day-night fluctuations during life.
It is of interest to note that in rats the maximal activity of the
hypocretin system takes place in their active period, i.e. at night
(Mileykovskiy et al., 2005; Yoshida et al., 2001) Surprisingly, we found
the highest hypocretin-1-ir levels in the human hypothalamus at
night. However, this observation agrees with two human studies that
reported the lowest CSF hypocretin levels during the daytime
(Salomon et al., 2003; Grady et al., 2006). This means that the nocturnal
elevation of hypocretin-1-ir in the hypothalamus is not simply due to a
lack of transport or secretion. A similar phenomenon was observed for
melatonin,which is also involved in sleep-wake control: in rats,melato-
nin levels increase during the dark period (their active phase) and de-
crease during the light period (rest phase) (Gutjahr et al., 2004), while
in humans its levels increase during the dark period (rest phase) and
decrease during the light period (active phase) (Zeitzer et al., 2007).
The possibility that the diurnal regulation systems act in a different
way in a diurnal and a nocturnal species (such as rodents) warrants fur-
ther investigation.
A recent study showed an age-related decline in the number of hy-
pothalamic hypocretin neurons in the range from 0 to 60 years of age
in control subjects (Hunt et al., 2015). We did not find such a correla-
tion, but it should be noted that, unlike in the study by others, the con-
trol subjects we studied did not contain very young ages.
4.2. PFC Hcrt-receptors in Depression and in Relation to Suicide
Earlier, our group found, with NBB cortex samples (depression pa-
tients without suicide), that the ACC seems to be more vulnerablethan the DLPFC to alterations in depression-related molecules, such as
nitric oxide synthase, gamma-aminobutyric acid and glutamate (Gao
et al., 2013; Zhao et al., 2012). In our study, with NBB cortex samples,
again we observed a trend for lower Hcrt-receptor-1-mRNA expression
in the ACC in depression but no changes in Hcrt-receptors in the DLPFC.
The novel findingwith SMRI cortex samples (containing depressive pa-
tients who committed suicide or died of causes other than suicide) that
therewas a significantly increasedHcrt-receptor-2-mRNAexpression in
the ACC, but not in the DLPFC, in male MDD patients who had commit-
ted suicide is in agreement with previous findings that the ACC is more
vulnerable to suicide than the DLPFC (Zhao et al., 2012; Drevets et al.,
2008) and that there is a sex difference in the prevalence of suicide
(Maguen et al., 2015). Our data concerning increased ACC Hcrt-recep-
tor-2-mRNA expression inmale suicide patients are thus interesting, al-
though too limited for a final conclusion. They do represent, however, a
strong rationale for further studies on this topic. Finally, the decreased
Hcrt-receptor-1-mRNA expression with aging we observed in the
DLPFC may at least partly explain the findings that in SMRI cortex sam-
ples (younger) both Hcrt-receptors were detectable in ACC and DLPFC,
while in the NBB series (older) Hcrt-receptor-1-mRNA expression was
only detectable in ACC and Hcrt-receptor-2-mRNA expression was
only detectable in the DLPFC.
Some concerns of the present postmortem brain material study
should be mentioned. We did not find significant differences in the hy-
pothalamic hypocretin-1-ir expression between MDD and BD patients,
which is in accordance with our previous findings for CRH, AVP and
OXT and for receptors in the hypothalamus (Bao et al., 2005; Wang et
al., 2008), although a final conclusion on this phenomenon should be
based upon a larger sample size. Secondly, one of the inherent potential
confounding factors in a postmortem study ismedication use. However,
we do not think that ourmain conclusions are cofounded by antidepres-
sants, since increased hypothalamic hypocretin-1-ir was only observed
in female depressive patients and increased expression of Hcrt-recep-
tor-2-mRNA in the ACC was only observed in male depressive suicides,
although all the depressive groups had been on antidepressants. In
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and Korpi, 2012), haloperidol (Dalal et al., 2003) and fluoxetine
(Nollet et al., 2011), taken by the depressive patients in the present
study, may inhibit hypocretin neurons and/or decrease hypocretin
levels. Therefore, had antidepressants interfered with our measure-
ments, this would have led to an underestimation of the increased
hypocretin-1 levels observed in female depressive patients. It is noted
that Calegare et al. found that sub-chronic treatment of adult male rats
with fluoxetine increased the levels of prepro-hypocretin mRNA in the
hypothalamus without affecting the hypocretin-1 CSF levels (Calegare
et al., 2016). In our study, there were 2 out of 10 male depression pa-
tients who had taken fluoxetine, while their hypothalamic hypocretin-
1-ir levels (IOD: 0.128 and 0.134) were fully within the range of the
other male depression patients (IOD range from 0.103 to 0.248, median
value 0.166). Finally, it should also be noted that the Hcrt-receptor data
are based upon mRNA measurements and have yet to be confirmed on
the protein level.
5. Conclusions
A clear sex-related change was found in the hypothalamic
hypocretin-1-ir in depression. The CUMS rat depression model did not
replicate changes found in the hypocretin systems in the human brain
in depression. Since sex-related changes in hypothalamic hypocretin-
1-ir expression were observed in depression, this factor should be
taken into account in the development of hypocretin-targeted thera-
peutic strategies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2017.03.043.
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